gabapentin has been researched along with Alcoholism in 55 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 7.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)." | 5.56 | Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020) |
| " The primary objective of this study was to compare the efficacy of gabapentin to lorazepam in alleviating sleep disturbances and daytime sleepiness during an episode of alcohol withdrawal." | 5.12 | Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. ( Boyle, E; Malcolm, R; Myrick, LH; Randall, PK; Veatch, LM, 2007) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 3.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| " Under gabapentin (1800 mg/day) and placebo (0 mg/day) maintenance, participants completed nine separate test sessions (three sessions per week) during which they received an oral solution containing 0, 15, or 30 mg/70 kg OXY in combination with 0, 0." | 3.11 | Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. ( Castillo, F; Comer, SD; Evans, SM; Foltin, RW; Jones, JD; Luba, RR; Mogali, S, 2022) |
| "Gabapentin treatment rapidly titrated to a dosage of 3600 mg/day is associated with a reduction in the proportion of HDD per week and an increase in PDA per week in actively drinking outpatients with AUD." | 3.01 | Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder. ( Basaraba, C; Bisaga, A; Brooks, DJ; Carpenter, KM; Levin, FR; Mamczur-Fuller, A; Mariani, JJ; Nunes, EV; Pavlicova, M, 2021) |
| "More gabapentin-treated individuals had no heavy drinking days (12 of 44 participants [27%]) compared with placebo (4 of 46 participants [9%]), a difference of 18." | 2.94 | Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. ( Anton, RF; Book, S; Bristol, E; Hoffman, M; Latham, P; Prisciandaro, J; Voronin, K, 2020) |
| "Pharmacological treatments for alcohol use disorder show a modest effect, and they are unavailable in certain countries." | 2.87 | A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence. ( Chompookham, P; Kalayasiri, R; Nilaban, S; Rukngan, W; Suwanmajo, S; Yoosom, P, 2018) |
| "Gabapentin is an antiepileptic medication with evidence of benefit in alcohol use disorder patients." | 2.82 | Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis. ( Kersten, B; Kunadharaju, R; Mammen, MJ; Mattle, AG; McGrath, P; Sanu, A; Zammit, K, 2022) |
| "Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics." | 2.79 | Gabapentin treatment for alcohol dependence: a randomized clinical trial. ( Begovic, A; Goodell, V; Kyle, M; Mason, BJ; Quello, S; Shadan, F, 2014) |
| "Gabapentin was associated with significantly greater reductions than placebo on several measures of subjective craving for alcohol as well as for affectively evoked craving." | 2.74 | Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. ( Drobes, DJ; Light, JM; Mason, BJ; Williams, LD, 2009) |
| "Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently." | 2.74 | Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. ( Anton, RF; Baros, AM; Latham, PK; Malcolm, R; Myrick, H; Randall, PK; Stewart, SH; Waid, R; Wright, TM, 2009) |
| "GABAPENTIN REDUCES WITHDRAWAL SYMPTOMS AND IS LESS SEDATING THAN BENZODIAZEPINES (SOR: B, BASED ON 1 MEDIUM-QUALITY RCT)." | 2.72 | Which detoxification regimens are effective for alcohol withdrawal syndrome? ( Caspar, R; Fortenberry, K; Leiser, J; Nashelsky, J; Ose, D, 2021) |
| "Seventeen volunteers without alcohol dependence were tested using a double-blind design with three 3-day long inpatient phases, each separated by at least a 1-week wash-out period." | 2.72 | The acute effects of gabapentin in combination with alcohol in heavy drinkers. ( Bisaga, A; Evans, SM, 2006) |
| "Gabapentin is a calcium channel GABAergic modulator that is widely used for pain." | 2.58 | Gabapentin for the treatment of alcohol use disorder. ( Mason, BJ; Quello, S; Shadan, F, 2018) |
| "Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications." | 2.52 | Assessment and treatment of insomnia in adult patients with alcohol use disorders. ( Brower, KJ, 2015) |
| "Studies evaluating gabapentin for alcohol dependence demonstrated dose-dependent benefits for complete abstinence, rates of no heavy drinking, and cravings." | 2.52 | The role of gabapentin in the management of alcohol withdrawal and dependence. ( Hall-Flavin, D; Leung, JG; Nelson, S; Schak, KM; Schmidt, KA, 2015) |
| "Substance use is prevalent in Canada, yet treatment is inaccessible." | 1.56 | A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. ( Hulme, J; Sheikh, H; Wiercigroch, D, 2020) |
| " Recent evidence suggests safety concerns associated with gabapentin including adverse neurologic effects." | 1.56 | Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. ( Bryant, KJ; Fiellin, DA; Justice, AC; Morford, KL; Rentsch, CT; Tate, JP, 2020) |
| "Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)." | 1.56 | Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020) |
| "Current medications for alcohol use disorder (AUD) have limited efficacy and utilization." | 1.51 | Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. ( Bryant, KJ; Fiellin, DA; Justice, AC; Rentsch, CT; Tate, JP, 2019) |
| "Gabapentin effects were blocked in the presence of a specific GABA(B) receptor antagonist." | 1.35 | Cellular and behavioral interactions of gabapentin with alcohol dependence. ( Cruz, MT; Gilpin, NW; Koob, GF; Morse, AC; O'Dell, LE; Roberto, M; Siggins, GR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.45) | 18.2507 |
| 2000's | 16 (29.09) | 29.6817 |
| 2010's | 16 (29.09) | 24.3611 |
| 2020's | 20 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Vannier, AGL | 1 |
| Shay, JES | 1 |
| Fomin, V | 1 |
| Patel, SJ | 1 |
| Schaefer, E | 1 |
| Goodman, RP | 1 |
| Luther, J | 1 |
| Leung, E | 1 |
| Ngo, DH | 1 |
| Espinoza, JA | 1 |
| Beal, LL | 1 |
| Chang, C | 1 |
| Baris, DA | 1 |
| Lackey, BN | 1 |
| Lane, SD | 1 |
| Wu, HE | 1 |
| Bahji, A | 1 |
| Crockford, D | 1 |
| El-Guebaly, N | 1 |
| Castillo, F | 1 |
| Jones, JD | 1 |
| Luba, RR | 1 |
| Mogali, S | 1 |
| Foltin, RW | 1 |
| Evans, SM | 2 |
| Comer, SD | 1 |
| Mocanu, V | 1 |
| Wood, E | 1 |
| Mattle, AG | 3 |
| McGrath, P | 3 |
| Sanu, A | 3 |
| Kunadharaju, R | 3 |
| Kersten, B | 3 |
| Zammit, K | 3 |
| Mammen, MJ | 3 |
| DeFoster, RE | 1 |
| Morgan, RJ | 1 |
| Leung, JG | 2 |
| Schenzel, H | 1 |
| Vijapura, P | 1 |
| Kashiwagi, DT | 1 |
| Fischer, KM | 1 |
| Philbrick, KL | 1 |
| Kung, S | 1 |
| Ahmed, S | 1 |
| Stanciu, CN | 1 |
| Kotapati, PV | 1 |
| Ahmed, R | 1 |
| Bhivandkar, S | 1 |
| Khan, AM | 1 |
| Afridi, A | 1 |
| Qureshi, M | 1 |
| Esang, M | 1 |
| Andaluz, A | 1 |
| DeMoss, D | 1 |
| Claassen, C | 1 |
| Blair, S | 1 |
| Hsu, J | 1 |
| Bakre, S | 1 |
| Khan, M | 1 |
| Atem, F | 1 |
| Rush, AJ | 1 |
| Wiercigroch, D | 1 |
| Sheikh, H | 1 |
| Hulme, J | 1 |
| Anton, RF | 6 |
| Latham, P | 1 |
| Voronin, K | 3 |
| Book, S | 2 |
| Hoffman, M | 2 |
| Prisciandaro, J | 1 |
| Bristol, E | 2 |
| Rentsch, CT | 2 |
| Morford, KL | 1 |
| Fiellin, DA | 2 |
| Bryant, KJ | 2 |
| Justice, AC | 2 |
| Tate, JP | 2 |
| Cheng, YC | 1 |
| Huang, YC | 1 |
| Huang, WL | 1 |
| Rose, M | 1 |
| Andrade, C | 1 |
| Morley, KC | 1 |
| Perry, CJ | 1 |
| Watt, J | 1 |
| Hurzeler, T | 1 |
| Leggio, L | 1 |
| Lawrence, AJ | 1 |
| Haber, P | 1 |
| Caspar, R | 1 |
| Fortenberry, K | 1 |
| Leiser, J | 1 |
| Ose, D | 1 |
| Nashelsky, J | 1 |
| Weresch, J | 1 |
| Kirkwood, J | 1 |
| Korownyk, CS | 1 |
| Mariani, JJ | 1 |
| Pavlicova, M | 1 |
| Basaraba, C | 1 |
| Mamczur-Fuller, A | 1 |
| Brooks, DJ | 1 |
| Bisaga, A | 2 |
| Carpenter, KM | 1 |
| Nunes, EV | 2 |
| Levin, FR | 1 |
| Bertholet, N | 1 |
| Prisciandaro, JJ | 1 |
| Brown, TR | 1 |
| Mason, BJ | 3 |
| Quello, S | 2 |
| Shadan, F | 2 |
| Pakri Mohamed, RM | 1 |
| Kumar, J | 1 |
| Ahmad, SU | 1 |
| Mohamed, IN | 1 |
| Chompookham, P | 1 |
| Rukngan, W | 1 |
| Nilaban, S | 1 |
| Suwanmajo, S | 1 |
| Yoosom, P | 1 |
| Kalayasiri, R | 1 |
| Castrén, S | 1 |
| Mäkelä, N | 1 |
| Alho, H | 1 |
| Morrison, M | 1 |
| Udeh, E | 1 |
| Burak, M | 1 |
| Kranzler, HR | 1 |
| Feinn, R | 1 |
| Morris, P | 1 |
| Hartwell, EE | 1 |
| Goodell, V | 1 |
| Kyle, M | 1 |
| Begovic, A | 1 |
| Brower, KJ | 4 |
| Hall-Flavin, D | 1 |
| Nelson, S | 1 |
| Schmidt, KA | 1 |
| Schak, KM | 1 |
| Roberto, M | 1 |
| Gilpin, NW | 1 |
| O'Dell, LE | 1 |
| Cruz, MT | 1 |
| Morse, AC | 1 |
| Siggins, GR | 1 |
| Koob, GF | 1 |
| Myra Kim, H | 1 |
| Strobbe, S | 1 |
| Karam-Hage, MA | 1 |
| Consens, F | 1 |
| Zucker, RA | 1 |
| Clemens, KJ | 1 |
| Vendruscolo, LF | 1 |
| Light, JM | 1 |
| Williams, LD | 1 |
| Drobes, DJ | 1 |
| Bonnet, U | 2 |
| Specka, M | 2 |
| Hamzavi Abedi, R | 1 |
| Wiltfang, J | 1 |
| Scherbaum, N | 1 |
| Myrick, H | 7 |
| Baros, AM | 3 |
| Latham, PK | 3 |
| Randall, PK | 5 |
| Wright, TM | 3 |
| Stewart, SH | 1 |
| Waid, R | 1 |
| Malcolm, R | 3 |
| Waid, LR | 2 |
| Schacht, JP | 2 |
| O'Brien, CP | 1 |
| Li, X | 1 |
| Henderson, S | 2 |
| Perugi, G | 1 |
| Toni, C | 1 |
| Frare, F | 1 |
| Ruffolo, G | 1 |
| Moretti, L | 1 |
| Torti, C | 1 |
| Akiskal, HS | 1 |
| Karam-Hage, M | 2 |
| Banger, M | 1 |
| Leweke, FM | 1 |
| Müller, BW | 1 |
| Hashemi, T | 1 |
| Nyhuis, PW | 1 |
| Kutscher, S | 1 |
| Burtscheidt, W | 1 |
| Gastpar, M | 1 |
| Book, SW | 1 |
| Anton, R | 1 |
| Wang, W | 1 |
| Victorri-Vigneau, C | 1 |
| Guerlais, M | 1 |
| Jolliet, P | 1 |
| Myrick, LH | 1 |
| Veatch, LM | 1 |
| Boyle, E | 1 |
| Furieri, FA | 1 |
| Nakamura-Palacios, EM | 1 |
| Bailey, CP | 1 |
| Molleman, A | 1 |
| Little, HJ | 1 |
| Brady, KT | 1 |
| Chatterjee, CR | 1 |
| Ringold, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of O[NCT05594121] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | ||
| Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects[NCT02349477] | Phase 2 | 96 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Gabapentin for Abstinence Initiation in Alcohol Dependence[NCT01141049] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial[NCT02771925] | Phase 4 | 25 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to poor compliance of patients in the study.) | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Gabapentin Treatment of Alcohol Dependence[NCT00391716] | Phase 2 | 150 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome[NCT03012815] | Phase 4 | 88 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
| A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention[NCT00262639] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Gabapentin as an Adjunct to Naltrexone for Alcoholism[NCT00183196] | Phase 3 | 150 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670] | 140 participants (Anticipated) | Interventional | 2018-11-14 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome). (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Low AWS/Gabapentin | 2 |
| Low AWS/Placebo | 3 |
| High AWS/Gabapentin | 10 |
| High AWS/Placebo | 1 |
The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 8 |
| Placebo | 2 |
The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 12 |
| Placebo | 4 |
During the course of 8 weeks the medication aims to determine whether it is effective in reducing alcohol consumption, and promoting abstinence in alcohol-dependent patients. (NCT01141049)
Timeframe: assessed for up to 8 weeks, presented at week 8 of trial
| Intervention | percent of days abstinent (Mean) |
|---|---|
| Gabapentin | 50 |
| Placebo | 27.5 |
percent of heavy drinking days as defined as 5 drinks per day for males and 4 drinks per day for females over the course of a study week. (NCT01141049)
Timeframe: assesed over 8 weeks, presented for week 8 of trial
| Intervention | percent of heavy drinking days (Mean) |
|---|---|
| Gabapentin | 22.5 |
| Placebo | 53.9 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Alcohol Craving Questionnaire has 12 questions about alcohol craving which are each scored 1-7, then summed for a weekly score between 7 and 84, with higher scores indicating greater craving. Cumulative mean total craving scores are tested by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 33.66 |
| Gabapentin 1800mg Daily | 32.31 |
| Placebo Daily | 34.27 |
Rate of complete abstinence was defined as the number of participants who drank no alcohol during 12 weeks of treatment, where the denominator is the intent to treat population. Rate of heavy drinking abstinence is defined as no heavy drinking days while on study (4 or more for women, 5 or more for men). (NCT00391716)
Timeframe: 12-week
| Intervention | participants (Number) |
|---|---|
| Gabapentin 900mg Daily | 6 |
| Gabapentin 1800mg Daily | 8 |
| Placebo Daily | 2 |
Beck Depression Inventory II consists of 21 questions assessing depression symptoms answered with scores between 0 and 3, summed for a weekly total score between 0 and 63; higher scores indicate more depression. The cumulative mean total depression scores over the 12 week study are tested by ANOVA for differences in cumulative means between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 5.08 |
| Gabapentin 1800mg Daily | 3.62 |
| Placebo Daily | 5.40 |
The Pittsburgh Sleep Questionnaire Inventory consists of 9 questions about sleep habits which are answered on a scale of 0-3. Results are sorted into 7 sub scales re-scored 0-3, then sub scales are summed for a weekly total score between 0 and 21, with higher total scores indicating greater sleep impairment. Cumulative mean total sleep scores over the 12 weeks of study are assessed by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 4.04 |
| Gabapentin 1800mg Daily | 3.24 |
| Placebo Daily | 4.50 |
GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.07 |
| Benzodiazepine | -3.79 |
PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -8.12 |
| Benzodiazepine | -8.45 |
The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.03 |
| Benzodiazepine | 0.07 |
CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 13.15 |
| Benzodiazepine | 12.81 |
The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | hours (Mean) |
|---|---|
| Gabapentin | 44.91 |
| Benzodiazepine | 50.50 |
The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | milligrams (Mean) |
|---|---|
| Gabapentin | 5.2 |
| Benzodiazepine | 10.8 |
The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6
| Intervention | percent days (Mean) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 70.8 |
| Low CIWAar Placebo | 86.1 |
| High CIWAar Placebo | 75.9 |
| High CIWAar Flumazenil/Gabapentin | 95.9 |
percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial
| Intervention | percent of participants (Number) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 44 |
| Low CIWAar Placebo | 19 |
| High CIWAar Placebo | 33 |
| High CIWAar Flumazenil/Gabapentin | 71 |
Time to relapse drinking which is 5 standard drinks perday for males and 4 standard drinks per day for females. Subjects had a minimum of 4 days of abstinence prior to being entered into the protocol. (NCT00183196)
Timeframe: 16 weeks
| Intervention | days (Mean) |
|---|---|
| Naltrexone Plus Gabapentin and CBI | 69.9 |
| Naltrexone Plus Placebo and CBI | 59.6 |
| Placebo Plus Placebo Plus CBI | 57.3 |
15 reviews available for gabapentin and Alcoholism
| Article | Year |
|---|---|
Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review.
Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Gabapentin; Humans; Substance Withdrawal Syndrome | 2022 |
Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review.
Topics: Alcoholism; Anxiety; Anxiety Disorders; Comorbidity; Gabapentin; Humans; Male; Middle Aged; Randomiz | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review.
Topics: Alcoholism; Craving; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Substance Withdrawal Syn | 2019 |
Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Craving; Gabapentin; Humans; Pregabalin; Randomized Controlled Trials | 2020 |
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies.
Topics: Alcoholism; Europe; Gabapentin; Humans; Topiramate | 2021 |
Which detoxification regimens are effective for alcohol withdrawal syndrome?
Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Carbamazepine; Gabapentin; Humans; Substance Withdrawa | 2021 |
Gabapentin for the treatment of alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids | 2018 |
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; | 2018 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent | 2019 |
A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder.
Topics: Alcohol Abstinence; Alcoholism; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Randomized Co | 2019 |
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsych | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
Anxious to drink: gabapentin normalizes GABAergic transmission in the central amygdala and reduces symptoms of ethanol dependence.
Topics: Alcoholism; Amines; Amygdala; Animals; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Gabapentin; | 2008 |
Novel anticonvulsants in the treatment of alcoholism.
Topics: Alcohol Deterrents; Alcoholism; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
21 trials available for gabapentin and Alcoholism
| Article | Year |
|---|---|
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.
Topics: Alcoholism; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Ethanol; Gabapentin; Humans | 2022 |
Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Benzodiazepines; Gabapentin; Hospitals; Humans; Retr | 2023 |
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal | 2020 |
Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.
Topics: Adult; Alcoholism; Anticonvulsants; Female; Gabapentin; Humans; Male; Medication Adherence; Middle A | 2021 |
Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Gabapentin; gamma-Aminobutyric Acid; Glutamic Acid; | 2021 |
A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcoholism; Excitatory Amino Acid Antagonists; Female; Gabapentin; Hospital | 2018 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Dose-Res | 2008 |
Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.
Topics: Adult; Affect; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Amines; Arousal; Cues; C | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Brain; Cues; Cyclohexanecarboxylic Acids; Drug Therapy, | 2013 |
Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.
Topics: Acetates; Alcoholism; Amines; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids; | 2003 |
Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.
Topics: Acetates; Adult; Alcoholism; Amines; Analysis of Variance; Chi-Square Distribution; Cyclohexanecarbo | 2003 |
The acute effects of gabapentin in combination with alcohol in heavy drinkers.
Topics: Adult; Alcoholic Intoxication; Alcoholism; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dos | 2006 |
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.
Topics: Adult; Aged; Alcohol-Related Disorders; Alcoholism; Amines; Anticonvulsants; Cyclohexanecarboxylic A | 2007 |
Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin.
Topics: Adult; Aged; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disorders of Excessive Somnolence; Dou | 2007 |
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Amines; Blood-Brain Barrie | 2007 |
Gabapentin treatment of alcohol withdrawal.
Topics: Acetates; Adult; Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Amines; Anticonvulsants; | 1998 |
Gabapentin treatment for insomnia associated with alcohol dependence.
Topics: Acetates; Adult; Alcoholism; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Fema | 2000 |
19 other studies available for gabapentin and Alcoholism
| Article | Year |
|---|---|
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nal | 2022 |
A Retrospective Study of the Adjunctive Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study.
Topics: Adult; Alcoholism; Benzodiazepines; Drug Tapering; Female; Gabapentin; Humans; Lorazepam; Male; Midd | 2020 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergen | 2020 |
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder.
Topics: Accidental Falls; Alcoholism; Cohort Studies; Comorbidity; Confusion; Drug Interactions; Excitatory | 2020 |
Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms.
Topics: Alcohol Drinking; Alcoholism; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Withdrawal Synd | 2020 |
Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach.
Topics: Adult; Alcohol Abstinence; Alcohol-Related Disorders; Alcoholism; Excitatory Amino Acid Antagonists; | 2020 |
Gabapentin for alcohol use disorder.
Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome; Treatment Outcome | 2021 |
Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome | 2021 |
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Case-Control Studies; Comorbidity; Dose-Response Relationship, | 2019 |
Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal.
Topics: Acute Disease; Adult; Alcoholism; Electronic Health Records; Endpoint Determination; Female; GABA Ag | 2019 |
Gabapentin: a new addition to the armamentarium for alcohol dependence?
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Female; GABA Modulators; Gabapentin; gamma-Aminobut | 2014 |
Cellular and behavioral interactions of gabapentin with alcohol dependence.
Topics: Alcoholism; Amines; Amygdala; Animals; Behavior, Animal; Central Nervous System Depressants; Cyclohe | 2008 |
Severe protracted alcohol withdrawal syndrome: prevalence and pharmacological treatment at an inpatient detoxification unit--a naturalistic study.
Topics: Adult; Aged; Alcoholism; Amines; Anticonvulsants; Chlormethiazole; Clonazepam; Cyclohexanecarboxylic | 2009 |
Adapting treatment to patient problems.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combina | 2011 |
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
Topics: Acetates; Adult; Aged; Alcoholism; Amines; Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bip | 2002 |
Abuse, dependency and withdrawal with gabapentin: a first case report.
Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption.
Topics: Acetates; Alcoholism; Amines; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarbox | 1998 |
A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin.
Topics: Acetates; Adult; Alcohol Drinking; Alcoholism; Amines; Animals; Anticonvulsants; Comorbidity; Cycloh | 1999 |